CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced the achievement of a pre-clinical milestone in its alliance with Eisai Co., Ltd., triggering a $4 million milestone payment. Epizyme and Eisai entered a worldwide strategic alliance in March 2011 to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients. Under the terms of the agreement, Epizyme may earn more than $200M in research, development and sales milestones and up to double-digit royalties. Additionally, Eisai will fund 100 percent of R&D through human proof-of-concept, at which point Epizyme has the right to opt into a profit share and co-commercialization arrangement for the United States.
